Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Poster Presentations: Acute and Chronic Complications

520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway

  1. MEIJUN WANG,
  2. RIYING LIANG,
  3. FEN XU and
  4. MENGYIN CAI
  1. Guangzhou, China
Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-520-P
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Recent studies have indicated apoptosis to be a major contributor to the progression of Diabetic Kidney Disease. GLP-1 agonist such as Exenatide, which counteracts insulin resistance in humans with type 2 diabetes, has been shown to ameliorate Diabetic Kidney Disease in experimental models. In this study, we investigated whether exenatide could alleviate Diabetic Kidney Disease by apoptosis through SIRT1/TXNIP signal pathway. Male C57BL/6J mice challenged with a high-fat diet (HFD) for 12weeks were then treated with exenatide (HFD+exe) or normal saline(HFD+sal) by intraperitoneal injection for 8 weeks. The results revealed that Exenatide notably decreased body weight, urine albumin-to-creatinine ratio(ACR) and apoptosis in the kidney induced by HFD challenge. Western blot revealed the level of apoptosis were notably downregulated after exenatide treatment. In addition, the protein expression of SIRT1 was upregulated, whereas TXNIP was downregulated in the HFD+exe group. Collectively, the data indicate that Exenatide ameliorates Diabetic Kidney Disease by inhibiting apoptosis via SIRT1/TXNIP signal pathway.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure M. Wang: None. R. Liang: None. F. Xu: None. M. Cai: None.

  • © 2020 by the American Diabetes Association
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 69 (Supplement 1)

In this Issue

June 2020, 69(Supplement 1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway
MEIJUN WANG, RIYING LIANG, FEN XU, MENGYIN CAI
Diabetes Jun 2020, 69 (Supplement 1) 520-P; DOI: 10.2337/db20-520-P

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway
MEIJUN WANG, RIYING LIANG, FEN XU, MENGYIN CAI
Diabetes Jun 2020, 69 (Supplement 1) 520-P; DOI: 10.2337/db20-520-P
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Poster Presentations: Acute and Chronic Complications

  • 414-P: Hand-Grip Strength and Type 2 Diabetes Are Mutually Independent Predictors of Cardiovascular Events and of Mortality in Patients with Established Cardiovascular Disease
  • 587-P: The Relationship between Metabolic Index, Liver Enzyme Index, and the Incidence of Diabetes: The Jinchang Cohort Study
  • 472-P: The Profiles of MicroRNAs from Urinary Extracellular Vesicles (EVS) Prepared by Various Isolation Methods and Their Correlation with Serum EV MicroRNAs in Patients with Type 2 Diabetes and Diabetic Nephropathy
Show more Poster Presentations: Acute and Chronic Complications

P: Complications—Nephropathy—Clinical and Translational Research

  • 499-P: Clinical Validation of an AI-Enabled Prognostic Test (KidneyintelX) to Accurately Predict Rapid Kidney Function Decline in Patients with Type 2 Diabetic Kidney Disease
  • 525-P: Impact of Extracellular-to-Intracellular Fluid Volume Ratio on Albuminuria in People with Type 2 Diabetes: A Cross-Sectional and Retrospective Cohort Study
  • 515-P: Nonalbuminuric Diabetic Kidney Disease in Type 1 Diabetes: Incidence of Major Vascular Outcomes over a 10-Year Follow-Up
Show more P: Complications—Nephropathy—Clinical and Translational Research

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.